KR20230069983A - Cdk4 억제제의 고체 형태 - Google Patents

Cdk4 억제제의 고체 형태 Download PDF

Info

Publication number
KR20230069983A
KR20230069983A KR1020237012766A KR20237012766A KR20230069983A KR 20230069983 A KR20230069983 A KR 20230069983A KR 1020237012766 A KR1020237012766 A KR 1020237012766A KR 20237012766 A KR20237012766 A KR 20237012766A KR 20230069983 A KR20230069983 A KR 20230069983A
Authority
KR
South Korea
Prior art keywords
cancer
ppm
values
crystalline form
solid state
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020237012766A
Other languages
English (en)
Korean (ko)
Inventor
웨슬리 드윗 클락
주디스 게일 딜
브라이언 매튜 사마스
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20230069983A publication Critical patent/KR20230069983A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237012766A 2020-09-15 2021-09-13 Cdk4 억제제의 고체 형태 Ceased KR20230069983A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063078636P 2020-09-15 2020-09-15
US63/078,636 2020-09-15
US202163240268P 2021-09-02 2021-09-02
US63/240,268 2021-09-02
PCT/IB2021/058320 WO2022058871A1 (en) 2020-09-15 2021-09-13 Solid forms of a cdk4 inhibitor

Publications (1)

Publication Number Publication Date
KR20230069983A true KR20230069983A (ko) 2023-05-19

Family

ID=78000744

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012766A Ceased KR20230069983A (ko) 2020-09-15 2021-09-13 Cdk4 억제제의 고체 형태

Country Status (17)

Country Link
US (1) US12570641B2 (https=)
EP (2) EP4214202B1 (https=)
JP (2) JP7260606B2 (https=)
KR (1) KR20230069983A (https=)
CN (1) CN116507620B (https=)
AU (1) AU2021345531B2 (https=)
DK (1) DK4214202T3 (https=)
ES (1) ES3022913T3 (https=)
FI (1) FI4214202T3 (https=)
HU (1) HUE070846T2 (https=)
MX (1) MX2023003054A (https=)
PL (1) PL4214202T3 (https=)
PT (1) PT4214202T (https=)
SI (1) SI4214202T1 (https=)
TW (2) TWI809503B (https=)
WO (1) WO2022058871A1 (https=)
ZA (1) ZA202303655B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
AU2021345531B2 (en) 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor
US20250041298A1 (en) * 2021-12-02 2025-02-06 Pfizer Inc. Cdk4 inhibitor for the treatment of cancer
JP2025533719A (ja) 2022-07-29 2025-10-09 ファイザー・インク がんの治療のためのｋａｔ６阻害剤を含む投与レジメン
WO2024051702A1 (zh) * 2022-09-05 2024-03-14 浙江同源康医药股份有限公司 用作cdk4激酶抑制剂的化合物及其应用
CN120981721A (zh) 2023-03-30 2025-11-18 辉瑞大药厂 Kat6a作为用kat6a抑制剂治疗的预测性生物标志物和相关治疗方法
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
CN121368483A (zh) 2023-06-02 2026-01-20 辉瑞公司 雌激素受体降解剂与cdk4抑制剂的组合
EP4719405A1 (en) 2023-06-02 2026-04-08 Pfizer Inc. Methods and modified dosing regimens comprising a cdk4 inhibitor for the treatment of cancer
WO2025024388A1 (en) 2023-07-21 2025-01-30 Accutar Biotechnology Inc. Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors
WO2025104624A1 (en) 2023-11-14 2025-05-22 Pfizer Inc. Synthesis of 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1h-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-d-threo-pentitol
WO2025202871A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Methods for identifying biomarkers of treatment response and use thereof with a cdk4 inhibitor
WO2025202900A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer
WO2026025013A2 (en) 2024-07-26 2026-01-29 Pfizer Inc. Combination therapy using cdk4 inhibitors for cancer treatments

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
TW201105669A (en) 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
EP2970200A1 (en) 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
CN105111191B (zh) 2015-07-21 2018-06-08 上海皓元生物医药科技有限公司 一种用于合成cdk9抑制剂的关键中间体及其制备方法和用途
AU2017295863B2 (en) 2016-07-13 2022-07-07 Medic Life Sciences, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
PT3497103T (pt) 2016-08-15 2021-06-17 Pfizer Inibidores de piridopirimidinona cdk2/4/6
GEP20227433B (en) * 2018-04-26 2022-10-25 Pfizer 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
AU2021345531B2 (en) 2020-09-15 2024-02-29 Pfizer Inc. Solid forms of a CDK4 inhibitor

Also Published As

Publication number Publication date
ES3022913T3 (en) 2025-05-29
AU2021345531B2 (en) 2024-02-29
MX2023003054A (es) 2023-04-05
ZA202303655B (en) 2024-09-25
CN116507620B (zh) 2025-11-18
TW202216698A (zh) 2022-05-01
WO2022058871A1 (en) 2022-03-24
TWI809503B (zh) 2023-07-21
JP2022186995A (ja) 2022-12-15
PT4214202T (pt) 2025-04-11
CN116507620A (zh) 2023-07-28
EP4578450A2 (en) 2025-07-02
EP4214202A1 (en) 2023-07-26
SI4214202T1 (sl) 2025-05-30
TW202334125A (zh) 2023-09-01
DK4214202T3 (da) 2025-03-31
US12570641B2 (en) 2026-03-10
JP2022049005A (ja) 2022-03-28
FI4214202T3 (fi) 2025-04-25
US20230357211A1 (en) 2023-11-09
HUE070846T2 (hu) 2025-07-28
AU2021345531A1 (en) 2023-04-20
EP4578450A3 (en) 2025-07-16
BR112023004713A2 (pt) 2023-04-18
PL4214202T3 (pl) 2025-05-19
JP7260606B2 (ja) 2023-04-18
JP7291839B2 (ja) 2023-06-15
CA3195063A1 (en) 2022-03-24
EP4214202B1 (en) 2025-02-26

Similar Documents

Publication Publication Date Title
JP7291839B2 (ja) 固体形態のｃｄｋ４阻害薬
AU2021404974B2 (en) Solid forms of a cdk2 inhibitor
EP3125901B1 (en) Derivatives of cephalosporin for treating cancer
JP2025540560A (ja) Ｅｇｆｒ阻害剤のフマル酸塩、酒石酸塩、リンゴ酸塩、及びクエン酸塩
JP2025538076A (ja) Ｅｇｆｒ阻害剤のマロン酸塩及びグリコール酸塩
TW202027750A (zh) 治療癌症之套組及其方法
CA3195063C (en) Solid forms of the cdk4 inhibitor pf-07220060
RU2856216C1 (ru) Твердые формы ингибитора cdk4
WO2024233313A1 (en) Egfr inhibitor for treating cancers comprising atypical egfr mutations
RU2850825C1 (ru) Твердые формы ингибитора cdk2
HK40096368A (zh) Cdk2抑制剂的固体形式
HK40087859A (zh) Cdk4抑制剂的固体形式
BR112023004713B1 (pt) Formas sólidas de um inibidor de cdk4 e sua composição farmacêutica
WO2026080372A1 (en) Treatment of cancers comprising egfr extracellular and transmembrane mutations
HK40125945A (zh) Egfr抑制剂的延胡索酸盐、酒石酸盐、苹果酸盐和柠檬酸盐
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer
HK1233924B (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T13-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000